The effect of rIL-2/IFN-α immunotherapy on acturial survival (A), DFS (B), and relapse (C) in Hodgkin's patients who received immunotherapy (n = 24) versus historical controls (n = 25, TRT + R) after autologous bone marrow transplantation (P < .02, P < .042, and NS, respectively).